|
|
|
|
|
05.03.26 - 12:36
|
Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor (Benzinga)
|
|
|
Alexion refuses to pay Xencor for U.S. Ultomiris sales. Read Xencor's response and the new 2028 operating runway details.
Latest Ratings for XNCR
DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Feb 2022BMO CapitalInitiates Coverage OnOutperform Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy
View More Analyst Ratings for XNCR
View the Latest Analyst Ratings
Importance Rank:
1
read more...
|
|
|
|
|
|
|
|
|
04.03.26 - 22:06
|
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast (Business Wire)
|
|
|
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals, Inc. (the “Licensee”) informed Xencor, Inc. (the “Company”) that it has taken the position that the Licensee does not owe any additional royalties for sales of Ultomiris® (ravulizumab-cwvz) in the United States and that the Licensee does not intend to make any future payments for sales in the United States. The Licensee informed the Company that it intends to continue making royalty payments for sales of Ultomiris outside the United States.
“Xencor has reasonably assumed that the multiple licensees of our XmAb Fc domains and technologies remit payments in accordance with the terms of their respective agreements. One licensee has expressed disagreement regarding payments for net sales of Ultomiris in the United States, and we plan to work toward a resolution in ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22.09.25 - 16:30
|
Xencor: Richtungsentscheidung im 4. Quartal (Sharedeals)
|
|
|
Xencor gehört zu den Biotech-Unternehmen, die mit innovativen Antikörperformaten ein großes medizinisches Potenzial erschließen wollen. Trotz zwischenzeitlicher Kursverluste bleibt die Pipeline vielfältig und aussichtsreich, sodass sich ein genauer Blick auf die aktuellen Entwicklungen lohnt. Fortschritte mit XmAb942 in der Behandlung entzündlicher Erkrankungen Xencor arbeitet kontinuierlich an der Weiterentwicklung seiner Plattform. Besonders im Fokus steht derzeit […]
The post Xencor: Richtungsentscheidung im 4. Quartal first appeared on sharedeals.de....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
